Tuesday Nov 22, 2022
Lead Story: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
NEJM
Results of a phase II trial testing the psychedelic compound in magic mushrooms as a treatment for depression have found that the drug psilocybin is effective, but not to the extent that earlier, smaller studies had suggested. The proportion of participants in remission after treatment dropped over time, raising questions about its durability and whether additional doses would be helpful. Among adults with treatment-resistant depression, a single dose of 25 mg of psilocybin, but not 10 mg, reduced depression severity significantly more than a 1-mg dose at 3 weeks. The trial did not compare psilocybin with existing treatments for depression and persons who were judged to be at a clinically significant risk for suicide were excluded from the trial.
Read this issue of the ASAM Weekly